Back to News
Market Impact: 0.2
Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
Source: GlobeNewswire
Healthcare & Biotech
ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial. The update reports tolerability only; no efficacy results were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook
- William Blair downgrades Alignment Healthcare stock rating on cost pressures